Command Palette

Search for a command to run...

Discover

Drugmakers Urge Supreme Court to Restore Telehealth Access to Mifepristone

Drugmakers Urge Supreme Court to Restore Telehealth Access to Mifepristone
View gallery

Drugmakers asked the U.S. Supreme Court on Saturday to immediately restore mail and telehealth access to the abortion pill mifepristone, one day after a federal appeals court ordered the drug can only be dispensed in person nationwide. The emergency applications set up a rapid, high‑stakes clash over both abortion access and the power of the Food and Drug Administration in an election year. nbcnews +1

A three‑judge panel of the U.S. Court of Appeals for the Fifth Circuit on Friday temporarily reinstated an FDA rule, dropped in 2021, that required patients to pick up mifepristone from a health provider rather than obtain it by mail or through telemedicine. The ruling applied not only to states that ban most abortions, like Louisiana, but also to states where abortion remains legal, and it came in a lawsuit brought by Louisiana against the FDA. nbcnews +1

What the Lower Courts Did — and Why

The Louisiana case targeted the FDA’s decision to allow mifepristone to be prescribed via telehealth and shipped by mail, arguing that the policy undermined the state’s near‑total abortion ban and imposed costs on its health system from alleged complications. The Fifth Circuit panel accepted Louisiana’s claim that out‑of‑state prescribers were mailing “streams of mifepristone” into the state for “thousands of abortions” each year, finding those asserted harms enough to give the state standing to sue. nytimes +1

In April, the trial judge had paused Louisiana’s lawsuit to let the FDA conduct an internal review, ordering a status update by October 7, 2026, and declining to immediately reinstate the in‑person rule. The Fifth Circuit intervened, calling that pause improper and ordering the old dispensing requirement back into effect nationwide while the case continues — an order that abortion‑rights groups said would “upend” how miscarriage and abortion care are delivered for patients who have relied on telemedicine, now used in more than one in four U.S. abortions. nytimes +1

Supreme Court Showdown Over FDA Authority and Abortion Access

Danco Laboratories and GenBioPro, which manufacture brand‑name and generic mifepristone, told the Supreme Court the Fifth Circuit’s move was “unprecedented,” warning it would cause “regulatory chaos” by disrupting a distribution system the FDA has deemed safe after more than 25 years of data. They argued that in 2024 the justices rejected similar standing claims in a related case, FDA v. Alliance for Hippocratic Medicine, when they ruled that anti‑abortion doctors lacked a concrete injury to challenge the agency’s easing of mifepristone restrictions. nytimes +2

The companies, backed by reproductive‑rights groups and many medical organizations, said the appeals court’s theory — that a state can sue whenever a federal drug policy allegedly complicates state law enforcement or shifts health‑care costs — could invite challenges to a wide range of FDA decisions, from vaccines to cancer drugs. Anti‑abortion officials in Louisiana and other states countered that the agency’s telehealth policy effectively nullified their abortion bans and that courts must step in when federal regulators overstep. The Fifth Circuit’s order immediately limited access to a drug used in nearly two‑thirds of U.S. abortions, forcing patients in many areas to travel for an in‑person pickup or consider alternative regimens. nbcnews +2

The Bigger Picture

How the Supreme Court handles the emergency requests will signal how far it is willing to let states and lower courts second‑guess FDA judgment — and how much of the post‑Dobbs abortion fight will be waged through the nation’s drug laws. A decision to keep the Fifth Circuit’s order in place would sharply curtail telehealth abortion nationwide and could embolden broader challenges to mifepristone and other medications; a decision to block it could reaffirm limits on who can sue over federal health‑care policy while leaving the underlying battle over abortion pills very much alive. nytimes +1